Kymera Therapeutic/$KYMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kymera Therapeutic
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Ticker
$KYMR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
208
ISIN
US5015751044
Website
KYMR Metrics
BasicAdvanced
$3B
-
-$3.11
2.19
-
Price and volume
Market cap
$3B
Beta
2.19
52-week high
$51.84
52-week low
$19.45
Average daily volume
950K
Financial strength
Current ratio
8.492
Quick ratio
8.191
Long term debt to equity
9.296
Total debt to equity
10.98
Interest coverage (TTM)
-1,004.44%
Profitability
EBITDA (TTM)
-271.67
Gross margin (TTM)
-361.38%
Net profit margin (TTM)
-409.07%
Operating margin (TTM)
-472.50%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-19.47%
Return on equity (TTM)
-32.17%
Valuation
Price to revenue (TTM)
61.033
Price to book
3.85
Price to tangible book (TTM)
3.85
Price to free cash flow (TTM)
-14.977
Free cash flow yield (TTM)
-6.68%
Free cash flow per share (TTM)
-310.08%
Growth
Revenue change (TTM)
-25.85%
Earnings per share change (TTM)
23.85%
3-year revenue growth (CAGR)
-2.61%
3-year earnings per share growth (CAGR)
7.73%
What the Analysts think about KYMR
Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.
Bulls say / Bears say
Kymera's KT-621, an oral STAT6 degrader, has shown promising preclinical data and is advancing into Phase 1 trials, potentially offering a significant alternative to existing treatments for Th2 inflammatory disorders. (investing.com)
The company maintains a strong financial position with $851 million in cash as of December 31, 2024, providing operational runway into mid-2027, supporting ongoing and future clinical developments. (stocktitan.net)
Analysts from BTIG Research initiated coverage with a 'Buy' rating and a $60.00 price target, indicating confidence in Kymera's growth prospects. (marketbeat.com)
Kymera reported a Q4 2024 loss of $0.88 per share, missing the consensus estimate of a $0.76 loss, raising concerns about financial performance. (stockinvest.us)
The company's net margin stands at -30.01%, indicating challenges in achieving profitability compared to industry standards. (markets.businessinsider.com)
Despite promising pipeline developments, the company faces significant competition in the biopharmaceutical sector, which could impact market share and revenue growth. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
KYMR Financial Performance
Revenues and expenses
KYMR Earnings Performance
Company profitability
KYMR News
AllArticlesVideos
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
MarketBeat·1 week ago
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
GlobeNewsWire·3 weeks ago
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kymera Therapeutic stock?
Kymera Therapeutic (KYMR) has a market cap of $3B as of June 20, 2025.
What is the P/E ratio for Kymera Therapeutic stock?
The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of June 20, 2025.
Does Kymera Therapeutic stock pay dividends?
No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Kymera Therapeutic dividend payment date?
Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Kymera Therapeutic?
Kymera Therapeutic (KYMR) has a beta rating of 2.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.